Exabis Library
Welcome to the e-CCO Library!
DOP021: Long-term efficacy of autologous haematopoietic stem cells transplantation for refractory Crohn’s disease: 10 years of Milan experience without CD34+ cell selection
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP022: Tacrolimus suppositories as induction therapy for refractory ulcerative proctitis: a randomised controlled trial
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP022: Tacrolimus suppositories as induction therapy for refractory ulcerative proctitis: A randomised controlled trial
2018
ECCO'18 Vienna
Tuesday, 8 May 2018, 11:36 AM
1
DOP022: Targeting immune cell metabolism: LYC-30937, a novel therapeutic approach for inflammatory bowel disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP022: Targeting Immune Cell Metabolism: LYC-30937, A Novel Therapeutic Approach for Inflammatory Bowel Disease
2016
ECCO'16 DOP
1
DOP022: Vedolizumab (VDZ) and anti-α treatment effectiveness in patients with IBD treated in Germany: A retrospective chart review
2017
ECCO'17 Barcelona
1
DOP022: Vedolizumab and anti-TNFα treatment effectiveness in patients with IBD treated in Germany: a retrospective chart review
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP023: Predictors of clinical and endoscopic response with vedolizumab for the treatment of moderately-severely active ulcerative colitis: results from the US VICTORY consortium
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP023: Predictors of clinical and endoscopic response with vedolizumab for the treatment of moderately-severely active Ulcerative Colitis: Results from the US VICTORY consortium
2017
ECCO'17 Barcelona
1
DOP023: Safety and efficacy of a novel i.v. targeted pegylated liposomal prednisolone (Nanocort): results from a phase 2a study in patients with active ulcerative colitis
2016
ECCO'16 DOP
1
DOP023: Safety and efficacy of a novel IV targeted pegylated liposomal prednisolone product (Nanocort): results from a phase 2a study in patients with active ulcerative colitis
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP023: Tofacitinib for the treatment of ulcerative colitis: up to 4.4 years of safety data from global clinical trials
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP024: Electrical vagus nerve stimulation as an innovative treatment in inflammatory bowel diseases
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP024: Electrical vagus nerve stimulation as an innovative treatment in inflammatory bowel diseases
2016
ECCO'16 DOP
1
DOP024: Tofacitinib achieves symptomatic improvement within 3 days in moderately to severely active ulcerative colitis, regardless of prior tumour necrosis factor inhibitor treatment status: results from OCTAVE induction 1 and 2
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP024: Tofacitinib achieves symptomatic improvement within three days in moderately to severely active Ulcerative Colitis, regardless of prior tumour necrosis factor inhibitor treatment status: Results from OCTAVE induction 1 2
2018
ECCO'18 Vienna
Tuesday, 8 May 2018, 11:36 AM
1
DOP024: Vedolizumab clinical and post-marketing safety experience of opportunistic infections
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP024: Vedolizumab clinical and post-marketing safety experience of opportunistic infections
2017
ECCO'17 Barcelona
1
DOP025: Clinical response to anti-MMP9 antibody (GS-5745) is accompanied by histologic improvement in ulcerative colitis
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP025: Clinical response to anti-MMP9 antibody (GS-5745) is accompanied by histologic improvement in ulcerative colitis
2016
ECCO'16 DOP
1